Eli Lilly and Company

(New York Stock Exchange)
Back to all articles
Bullish +72

7,884 Shares in Eli Lilly and Company $LLY Purchased by Amova Asset ...

AI-generated analysis

πŸ“ˆ Amova Asset Management Americas Inc. purchased a new position of 7,884 shares in Eli Lilly valued at approximately $7.25 million in the first quarter.

🏦 Multiple institutional investors including Maryland Capital Advisors and Maseco LLP initiated or increased stakes in the fourth quarter, with Maseco growing holdings by 466.7%.

πŸ“Š Cantor Fitzgerald raised its target price to $1,350 with an overweight rating, while Truist Financial lifted its objective to $1,370 with a buy rating.

πŸ’° Eli Lilly reported quarterly EPS of $8.55, beating the consensus estimate of $6.97 by $1.58 in the quarter ended April 30th.

πŸ“ˆ Revenue reached $19.80 billion, exceeding analyst estimates of $17.82 billion and growing 55.5% compared to the same quarter last year.

🎯 The company set full-year 2026 EPS guidance between $35.50 and $37.00, slightly above the consensus expectation of $34.55.

πŸ’΅ A quarterly dividend of $1.73 was announced with an ex-dividend date of August 14th and a payment date of September 10th.

πŸ“‰ The stock trades at a PEG ratio of 1.48 with a market capitalization of $1.08 trillion and a price-to-earnings ratio of 40.74.

πŸ“‰ Wall Street Zen downgraded the stock from strong-buy to buy, though the consensus rating remains Moderate Buy with a target of $1,283.64.

🏒 Hedge funds and other institutional investors collectively own 82.53% of the company's outstanding stock.

Bullish Signals
  • Eli Lilly significantly beat quarterly earnings estimates with EPS of $8.55 versus a consensus of $6.97, demonstrating strong profitability.
  • Revenue of $19.80 billion exceeded analyst expectations of $17.82 billion, highlighting robust demand for the company's products.
  • Year-over-year revenue growth of 55.5% indicates sustained business expansion and market share gains.
  • Cantor Fitzgerald raised its price target to $1,350 with an overweight rating, signaling strong analyst confidence in future performance.
  • Truist Financial increased its price objective to $1,370 while maintaining a buy rating, reinforcing positive sentiment among major banks.
  • Guggenheim lifted its price target to $1,273 and reaffirmed a buy rating, contributing to the consensus Moderate Buy status.
  • The company maintains a high return on equity of 105.77%, reflecting efficient capital utilization and strong operational leverage.
  • Full-year 2026 EPS guidance of $35.50-$37.00 exceeds analyst consensus of $34.55, indicating management's confidence in future growth.
Risk Factors
  • Wall Street Zen downgraded the stock from strong-buy to buy, reflecting some caution among analysts despite recent positive earnings.
  • The dividend yield is relatively low at 0.6%, which may limit appeal for income-focused investors compared to other sectors.
Full Analysis
Amova Asset Management Americas Inc. established a new position in Eli Lilly and Company (NYSE:LLY) during the first quarter, purchasing 7,884 shares valued at approximately $7.25 million. Several other institutional investors, including Maryland Capital Advisors, Osbon Capital Management, Basso Capital Management, Maseco LLP, and E Fund Management Hong Kong Co. Ltd., also initiated or increased their stakes in the fourth quarter, with holdings ranging from roughly $25,000 to $31,000. Wall Street analysts have recently issued mixed but generally positive ratings on Eli Lilly stock. Cantor Fitzgerald raised its target price to $1,350 with an overweight rating, while Truist Financial and Guggenheim lifted their price objectives to $1,370 and $1,273 respectively, both maintaining buy ratings. Goldman Sachs reaffirmed a buy rating at $1,283, though Wall Street Zen downgraded the stock from strong-buy to buy. The consensus target price stands at $1,283.64 with an average rating of Moderate Buy. Financially, Eli Lilly reported strong quarterly results ending April 30th, beating earnings estimates significantly with $8.55 EPS compared to a consensus of $6.97. Revenue reached $19.80 billion, surpassing analyst expectations of $17.82 billion and representing a 55.5% year-over-year increase. The company maintains a robust balance sheet with a market cap of $1.08 trillion, a PEG ratio of 1.48, and has set full-year 2026 EPS guidance between $35.50 and $37.00. The company recently announced a quarterly dividend of $1.73 per share, payable on September 10th to shareholders of record on August 14th, resulting in an annualized dividend yield of 0.6%. Currently trading around $1,146.90, the stock sits above its 50-day and 200-day moving averages. With a debt-to-equity ratio of 1.26 and a return on equity of 105.77%, Eli Lilly continues to demonstrate strong operational performance and financial health.